All In MedTech

FDA Clearance Tracker · P150027-S003

PD-L1 IHC 28-8 PHARMDX

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 24, 2017

Approved

Time to decision

179 days

Received Aug 29, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150027-S003
Device name
PD-L1 IHC 28-8 PHARMDX
Applicant location
Carpinteria, CA
Received
Aug 29, 2016
Decided
Feb 24, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P150027

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the updated product labeling and associated data.

Source documents

Other decisions for Dako North America, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.